The acellular therapy market size has grown rapidly in recent years. It will grow from $8.3 billion in 2025 to $9.69 billion in 2026 at a compound annual growth rate (CAGR) of 16.7%. The growth in the historic period can be attributed to increasing research activity in regenerative medicine, early clinical adoption of acellular matrices, growing demand for immune-safe therapies, expansion of wound care applications, improvements in biomaterial processing techniques.
The acellular therapy market size is expected to see rapid growth in the next few years. It will grow to $18.09 billion in 2030 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to rising demand for personalized regenerative treatments, increasing investments in advanced biomaterials, expansion of clinical indications for acellular therapies, growing focus on scalable regenerative solutions, increasing regulatory support for non-cellular therapies. Major trends in the forecast period include increasing adoption of growth factor-based therapies, rising use of extracellular matrix scaffolds, growing focus on cell-free regenerative solutions, expansion of off-the-shelf regenerative products, enhanced integration of translational research platforms.
The increasing adoption of regenerative medicine is anticipated to drive the growth of the acellular therapy market in the coming years. Regenerative medicine refers to medical approaches that repair, replace, or regenerate human cells, tissues, or organs by harnessing biological processes and therapies to restore normal function. Adoption of regenerative medicine is increasing as biotechnology research activity expands globally, with more developers, deeper pipelines, and broader therapeutic exploration. Acellular therapy (AT) supports this trend by providing bioactive, cell-free therapeutic materials, such as extracellular vesicles, secretomes, and other biologically active components, which complement regenerative strategies with enhanced safety and standardized dosing. For example, in June 2024, according to the Centre for Commercialization of Regenerative Medicine (CCRM), a Canada-based regenerative medicine organization, there were 2,848 cell and gene therapy developers worldwide as of April 2024, up 11% from Q4 2023, and 1,751 active regenerative medicine clinical trials globally as of April 2024, reflecting sustained clinical engagement and growth in regenerative research activity. Therefore, the increasing adoption of regenerative medicine is driving the growth of the acellular therapy market.
Companies operating in the acellular therapy market are focusing on developing small extracellular vesicle (sEV) therapies to enhance tissue regeneration, reduce inflammation, and modulate immune responses by delivering bioactive vesicles directly to affected tissues without introducing living cells. Small extracellular vesicle (sEV) therapies refer to acellular products derived from cultured cells that carry proteins, ribonucleic acids (RNAs), and signaling molecules, enabling targeted modulation of cellular activity, repair of damaged tissue, and immunomodulation. For example, in March 2025, evast bio, a US-based biotechnology company, developed small extracellular vesicle (sEV) therapy for knee osteoarthritis, which was designed to address key challenges in inflammatory joint disease. The therapy delivers exosomes to inflamed cartilage, promotes regeneration of cartilage extracellular matrix, reduces inflammatory markers, and improves joint function, making it a pioneering acellular therapy (AT) for musculoskeletal inflammation and a model for future extracellular vesicle (sEV)-based treatments.
In April 2023, AGC Biologics, a US-based global biopharmaceutical contract development and manufacturing organization (CDMO), partnered with the Jikei University School of Medicine. Through this collaboration, AGC Biologics will lead a feasibility study and technology transfer to develop an exosome-based therapeutic candidate derived from bronchial epithelial cells for the treatment of idiopathic pulmonary fibrosis (IPF). Exosomes are acellular therapies that deliver bioactive molecules without introducing living cells, supporting regenerative medicine and anti-inflammatory applications. The Jikei University is a Japan-based medical research institution pioneering extracellular vesicle-based therapeutics for respiratory and inflammatory diseases.
Major companies operating in the acellular therapy market are Thermo Fisher Scientific, FUJIFILM Holdings Corp., Lonza Group AG, Smith+Nephew, Charles River Laboratories, Sartorius AG, Integra LifeSciences, AGC Biologics, Organogenesis Holdings Inc., MiMedx Group Inc., Vericel Corporation, Avita Medical, Capricor Therapeutics, RoosterBio Inc., Creative Biolabs, Evox Therapeutics Ltd., ILIAS Biologics, Aruna Biomedical, Stem Cell Medicine Ltd., Aegle Therapeutics Corp, Direct Biologics LLC., BioCardia Inc., BioRestorative Therapies Inc., and EverZom.
Tariffs are influencing the acellular therapy market by increasing costs of imported biomaterials, purification equipment, laboratory consumables, and specialized processing technologies used in scaffold production and regenerative formulations. Research institutes, hospitals, and specialty clinics in North America and Europe are most affected due to dependence on imported high-grade biological materials, while Asia-Pacific faces cost pressure on translational research manufacturing. These tariffs are increasing development and treatment costs and slowing commercialization timelines. At the same time, they are supporting local biomaterial sourcing, regional manufacturing expansion, and investment in domestic regenerative medicine infrastructure.
The acellular therapy market research report is one of a series of new reports that provides acellular therapy market statistics, including acellular therapy industry global market size, regional shares, competitors with a acellular therapy market share, detailed acellular therapy market segments, market trends and opportunities, and any further data you may need to thrive in the acellular therapy industry. This acellular therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Acellular therapy is a regenerative and therapeutic method that relies on biologically active elements such as growth factors, cytokines, extracellular vesicles, or refined matrix substances rather than live cells to encourage tissue regeneration, regulate immune activity, and support healing. This approach seeks to capture the positive effects of cellular signaling and structural support while lowering risks linked to cell transplantation, including immune rejection, tumor development, and complex storage or handling needs.
The primary types of acellular therapy include acellular dermal matrices (ADM), acellular amniotic membranes, acellular umbilical cord products, and other categories. Acellular dermal matrices (ADM) are biologically sourced scaffolding materials that offer structural reinforcement and promote tissue regeneration while lacking living cells. These therapies are utilized for conditions such as Parkinson’s disease, Alzheimer’s disease, chronic wounds, sclerosis, and cancer. They are implemented using multiple scaffold formats, including fused deposition modeling (FDM), cell-laden hydrogels, extracellular matrix (ECM), and selective laser sintering (SLS). The application areas include hepatology, orthopedics, cardiology, neurology, oncology, and gastroenterology, while the end users consist of hospitals, clinics, ambulatory surgical centers, and research institutes.
The acellular therapy market includes revenues earned by entities through regenerative medicine treatment services, immunomodulatory therapy services, aesthetic and anti-aging regenerative services, and clinical research and translational therapy services. The market value includes the value of related goods and services provided by the manufacturers or developers. Only goods and services traded between entities or sold to institutions are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The acellular therapy market size is expected to see rapid growth in the next few years. It will grow to $18.09 billion in 2030 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to rising demand for personalized regenerative treatments, increasing investments in advanced biomaterials, expansion of clinical indications for acellular therapies, growing focus on scalable regenerative solutions, increasing regulatory support for non-cellular therapies. Major trends in the forecast period include increasing adoption of growth factor-based therapies, rising use of extracellular matrix scaffolds, growing focus on cell-free regenerative solutions, expansion of off-the-shelf regenerative products, enhanced integration of translational research platforms.
The increasing adoption of regenerative medicine is anticipated to drive the growth of the acellular therapy market in the coming years. Regenerative medicine refers to medical approaches that repair, replace, or regenerate human cells, tissues, or organs by harnessing biological processes and therapies to restore normal function. Adoption of regenerative medicine is increasing as biotechnology research activity expands globally, with more developers, deeper pipelines, and broader therapeutic exploration. Acellular therapy (AT) supports this trend by providing bioactive, cell-free therapeutic materials, such as extracellular vesicles, secretomes, and other biologically active components, which complement regenerative strategies with enhanced safety and standardized dosing. For example, in June 2024, according to the Centre for Commercialization of Regenerative Medicine (CCRM), a Canada-based regenerative medicine organization, there were 2,848 cell and gene therapy developers worldwide as of April 2024, up 11% from Q4 2023, and 1,751 active regenerative medicine clinical trials globally as of April 2024, reflecting sustained clinical engagement and growth in regenerative research activity. Therefore, the increasing adoption of regenerative medicine is driving the growth of the acellular therapy market.
Companies operating in the acellular therapy market are focusing on developing small extracellular vesicle (sEV) therapies to enhance tissue regeneration, reduce inflammation, and modulate immune responses by delivering bioactive vesicles directly to affected tissues without introducing living cells. Small extracellular vesicle (sEV) therapies refer to acellular products derived from cultured cells that carry proteins, ribonucleic acids (RNAs), and signaling molecules, enabling targeted modulation of cellular activity, repair of damaged tissue, and immunomodulation. For example, in March 2025, evast bio, a US-based biotechnology company, developed small extracellular vesicle (sEV) therapy for knee osteoarthritis, which was designed to address key challenges in inflammatory joint disease. The therapy delivers exosomes to inflamed cartilage, promotes regeneration of cartilage extracellular matrix, reduces inflammatory markers, and improves joint function, making it a pioneering acellular therapy (AT) for musculoskeletal inflammation and a model for future extracellular vesicle (sEV)-based treatments.
In April 2023, AGC Biologics, a US-based global biopharmaceutical contract development and manufacturing organization (CDMO), partnered with the Jikei University School of Medicine. Through this collaboration, AGC Biologics will lead a feasibility study and technology transfer to develop an exosome-based therapeutic candidate derived from bronchial epithelial cells for the treatment of idiopathic pulmonary fibrosis (IPF). Exosomes are acellular therapies that deliver bioactive molecules without introducing living cells, supporting regenerative medicine and anti-inflammatory applications. The Jikei University is a Japan-based medical research institution pioneering extracellular vesicle-based therapeutics for respiratory and inflammatory diseases.
Major companies operating in the acellular therapy market are Thermo Fisher Scientific, FUJIFILM Holdings Corp., Lonza Group AG, Smith+Nephew, Charles River Laboratories, Sartorius AG, Integra LifeSciences, AGC Biologics, Organogenesis Holdings Inc., MiMedx Group Inc., Vericel Corporation, Avita Medical, Capricor Therapeutics, RoosterBio Inc., Creative Biolabs, Evox Therapeutics Ltd., ILIAS Biologics, Aruna Biomedical, Stem Cell Medicine Ltd., Aegle Therapeutics Corp, Direct Biologics LLC., BioCardia Inc., BioRestorative Therapies Inc., and EverZom.
Tariffs are influencing the acellular therapy market by increasing costs of imported biomaterials, purification equipment, laboratory consumables, and specialized processing technologies used in scaffold production and regenerative formulations. Research institutes, hospitals, and specialty clinics in North America and Europe are most affected due to dependence on imported high-grade biological materials, while Asia-Pacific faces cost pressure on translational research manufacturing. These tariffs are increasing development and treatment costs and slowing commercialization timelines. At the same time, they are supporting local biomaterial sourcing, regional manufacturing expansion, and investment in domestic regenerative medicine infrastructure.
The acellular therapy market research report is one of a series of new reports that provides acellular therapy market statistics, including acellular therapy industry global market size, regional shares, competitors with a acellular therapy market share, detailed acellular therapy market segments, market trends and opportunities, and any further data you may need to thrive in the acellular therapy industry. This acellular therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Acellular therapy is a regenerative and therapeutic method that relies on biologically active elements such as growth factors, cytokines, extracellular vesicles, or refined matrix substances rather than live cells to encourage tissue regeneration, regulate immune activity, and support healing. This approach seeks to capture the positive effects of cellular signaling and structural support while lowering risks linked to cell transplantation, including immune rejection, tumor development, and complex storage or handling needs.
The primary types of acellular therapy include acellular dermal matrices (ADM), acellular amniotic membranes, acellular umbilical cord products, and other categories. Acellular dermal matrices (ADM) are biologically sourced scaffolding materials that offer structural reinforcement and promote tissue regeneration while lacking living cells. These therapies are utilized for conditions such as Parkinson’s disease, Alzheimer’s disease, chronic wounds, sclerosis, and cancer. They are implemented using multiple scaffold formats, including fused deposition modeling (FDM), cell-laden hydrogels, extracellular matrix (ECM), and selective laser sintering (SLS). The application areas include hepatology, orthopedics, cardiology, neurology, oncology, and gastroenterology, while the end users consist of hospitals, clinics, ambulatory surgical centers, and research institutes.
The acellular therapy market includes revenues earned by entities through regenerative medicine treatment services, immunomodulatory therapy services, aesthetic and anti-aging regenerative services, and clinical research and translational therapy services. The market value includes the value of related goods and services provided by the manufacturers or developers. Only goods and services traded between entities or sold to institutions are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Acellular Therapy Market Characteristics
3. Acellular Therapy Market Supply Chain Analysis
4. Global Acellular Therapy Market Trends and Strategies
5. Acellular Therapy Market Analysis Of End Use Industries
7. Global Acellular Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Acellular Therapy Total Addressable Market (TAM) Analysis for the Market
9. Acellular Therapy Market Segmentation
10. Acellular Therapy Market Regional and Country Analysis
11. Asia-Pacific Acellular Therapy Market
12. China Acellular Therapy Market
13. India Acellular Therapy Market
14. Japan Acellular Therapy Market
15. Australia Acellular Therapy Market
16. Indonesia Acellular Therapy Market
17. South Korea Acellular Therapy Market
18. Taiwan Acellular Therapy Market
19. South East Asia Acellular Therapy Market
20. Western Europe Acellular Therapy Market
21. UK Acellular Therapy Market
22. Germany Acellular Therapy Market
23. France Acellular Therapy Market
24. Italy Acellular Therapy Market
25. Spain Acellular Therapy Market
26. Eastern Europe Acellular Therapy Market
27. Russia Acellular Therapy Market
28. North America Acellular Therapy Market
29. USA Acellular Therapy Market
30. Canada Acellular Therapy Market
31. South America Acellular Therapy Market
32. Brazil Acellular Therapy Market
33. Middle East Acellular Therapy Market
34. Africa Acellular Therapy Market
36. Acellular Therapy Market Competitive Landscape and Company Profiles
37. Acellular Therapy Market Other Major and Innovative Companies
41. Acellular Therapy Market High Potential Countries, Segments and Strategies
42. Appendix
Executive Summary
Acellular Therapy Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses acellular therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for acellular therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The acellular therapy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Acellular Dermal Matrices; Acellular Amniotic Membranes; Acellular Umbilical Cord Products; Other Types2) By Disease: Parkinson’s; Alzheimer’s; Chronic Wounds; Sclerosis; Cancer
3) By Scaffold: Fused Deposition Modeling (FDM); Cell Laden Hydrogel; Extracellular Matrix (ECM); Selective Laser Sintering (SLS)
4) By Application: Hepatology; Orthopedic; Cardiology; Neurology; Oncology; Gastroenterology
5) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers; Research Institutes
Subsegments:
1) By Acellular Dermal Matrices: Human Derived Dermal Matrices; Animal Derived Dermal Matrices; Cross Linked Dermal Matrices; Non Cross Linked Dermal Matrices2) By Acellular Amniotic Membranes: Cryopreserved Amniotic Membranes; Dehydrated Amniotic Membranes; Lyophilized Amniotic Membranes; Laminated Amniotic Membranes
3) By Acellular Umbilical Cord Products: Wharton Jelly Based Products; Umbilical Cord Patch Products; Umbilical Cord Powder Products; Umbilical Cord Sheet Products
4) By Other Types: Acellular Cartilage Matrices; Acellular Bone Matrices; Acellular Vascular Grafts; Acellular Tendon and Ligament Scaffolds
Companies Mentioned: Thermo Fisher Scientific; FUJIFILM Holdings Corp.; Lonza Group AG; Smith+Nephew; Charles River Laboratories; Sartorius AG; Integra LifeSciences; AGC Biologics; Organogenesis Holdings Inc.; MiMedx Group Inc.; Vericel Corporation; Avita Medical; Capricor Therapeutics; RoosterBio Inc.; Creative Biolabs; Evox Therapeutics Ltd.; ILIAS Biologics; Aruna Biomedical; Stem Cell Medicine Ltd.; Aegle Therapeutics Corp; Direct Biologics LLC.; BioCardia Inc.; BioRestorative Therapies Inc.; and EverZom.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Acellular Therapy market report include:- Thermo Fisher Scientific
- FUJIFILM Holdings Corp.
- Lonza Group AG
- Smith+Nephew
- Charles River Laboratories
- Sartorius AG
- Integra LifeSciences
- AGC Biologics
- Organogenesis Holdings Inc.
- MiMedx Group Inc.
- Vericel Corporation
- Avita Medical
- Capricor Therapeutics
- RoosterBio Inc.
- Creative Biolabs
- Evox Therapeutics Ltd.
- ILIAS Biologics
- Aruna Biomedical
- Stem Cell Medicine Ltd.
- Aegle Therapeutics Corp
- Direct Biologics LLC.
- BioCardia Inc.
- BioRestorative Therapies Inc.
- and EverZom.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | March 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 9.69 Billion |
| Forecasted Market Value ( USD | $ 18.09 Billion |
| Compound Annual Growth Rate | 16.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
